Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Beta-caryophyllene is a natural bicyclic sesquiterpene found in many essential oils, such as clove, black pepper, and cannabis. Its use in supporting or treating Chronic Obstructive Pulmonary Disease (COPD) is based primarily on emerging scientific evidence rather than traditional medicine. Several preclinical studies have demonstrated that beta-caryophyllene acts as a selective agonist of the cannabinoid receptor type 2 (CB2), which is involved in modulating inflammation. In animal models of lung injury and inflammation, beta-caryophyllene has shown the ability to reduce inflammatory cytokine levels, oxidative stress, and tissue damage in lung tissue. For example, a 2014 study in "European Journal of Pharmacology" found that beta-caryophyllene attenuated lung inflammation in a mouse model of lipopolysaccharide-induced acute lung injury.

Despite these promising results, there are no published clinical trials or large-scale human studies directly assessing beta-caryophyllene's efficacy or safety in COPD patients. Thus, while the mechanistic rationale and preclinical data support its potential as an anti-inflammatory and cytoprotective agent for lung diseases such as COPD, the current level of evidence is still preliminary. More research, particularly well-designed human trials, is needed before beta-caryophyllene can be recommended as a treatment for COPD. Therefore, the evidence rating for its use in COPD is 2 out of 5—promising preclinical findings, but insufficient clinical validation at this time.

More about beta caryophyllene
More about Chronic Obstructive Pulmonary Disorder

Other ingredients used for Chronic Obstructive Pulmonary Disorder

Other health conditions supported by beta caryophyllene

Products containing beta caryophyllene